Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false statements or omissions [2][3][4] Financial Data - The financial statements for the third quarter are unaudited [3] - The report period refers to the three-month period from the beginning to the end of the quarter [3] - The company has a total of 4,690,088 shares held in the repurchase special securities account, accounting for 3.94% of the total share capital [4] Shareholder Information - There are no changes in the top ten shareholders or the top ten unrestricted circulating shareholders due to securities lending activities [5][6] Other Important Information - There are no additional important reminders regarding the company's operational situation during the reporting period [6]

Core Viewpoint - The recent operational status of various companies remains stable, with no significant changes in the internal and external business environment [1][3]. Performance - WuXi AppTec reported a net profit of 12.076 billion yuan for the first three quarters, an increase of 84.84% year-on-year [3]. - Cambridge Technology experienced a year-on-year net profit growth of 70.88% in the first three quarters [3]. - Huasheng Lithium Battery reported a net loss of 103 million yuan in the first three quarters [3]. - Weicai Technology achieved a net profit of 202 million yuan in the first three quarters, marking a 226.41% increase year-on-year [3]. - China Tungsten High-Tech reported a year-on-year net profit growth of 18.26% in the first three quarters [3]. - Guosheng Jinkong's net profit for the first three quarters was 242 million yuan, up 191.21% year-on-year [3]. - Zhenghai Magnetic Materials reported a net profit of 115 million yuan in the third quarter, a year-on-year increase of 189.72% [3]. - Wenzhou Hongfeng's net profit in the third quarter was 15.6016 million yuan, up 257.49% year-on-year [3]. - Xiyu Co. reported a net profit of 1.745 billion yuan for the first three quarters, an increase of 35.99% year-on-year [3]. - Shen Shen Fang A reported a staggering net profit growth of 2791.57% year-on-year in the first three quarters, totaling 14.5 million yuan [3]. - Bojun Technology achieved a net profit of 274 million yuan in the third quarter, a year-on-year increase of 102.11% [3]. - Huace Testing reported a net profit of 345 million yuan in the third quarter, up 11.24% year-on-year [3]. - Genesis reported a net profit of 115 million yuan in the third quarter, marking a 164.38% year-on-year increase [3]. - Tongguan Copper Foil reported a net profit of 62.7243 million yuan in the first three quarters, up 162.49% year-on-year [3]. Major Investments - Hengyu Environmental Protection signed a sales contract worth 14 million USD for an industrial continuous waste tire cracking production line [3]. - Ningbo Fangzheng entered a strategic cooperation agreement with Shandong Future Robot Co., Ltd. [3]. - Jushen Co. signed an aluminum ore transfer agreement [3]. Shareholding Changes - WuXi AppTec plans to transfer 100% equity of Kangde Hongyi and Jinshi Pharmaceutical [3]. - Zhongzhi Co. intends to transfer shares to Jiangsu Xinchang Microelectronics Group Co., Ltd. [3]. - Chenzhou International plans to invest in a joint venture for a photovoltaic power generation project [3]. - Bayi Steel plans to invest in a new 3500mm straightening machine project for its rolling mill [3]. Mergers and Acquisitions - Yingtang Zhikong is planning to acquire assets through share issuance, leading to a stock suspension [3]. - Yiyi Co. intends to acquire 100% equity of Gao Ye Family, with stock resuming trading [3]. - Huilv Ecology's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [3]. - China Tungsten High-Tech plans to acquire equity in Yuanjing Tungsten Industry [3]. Other - Sifang Jichuang plans to issue H-shares and list on the Hong Kong Stock Exchange [3]. - Hand Information plans to issue H-shares and list on the Hong Kong Stock Exchange [3].

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [5] Core Insights - The report highlights the significant performance of domestic new drugs showcased at the ESMO 2025 conference, with several companies presenting excellent clinical data [3][21] - The report emphasizes the importance of academic conferences as key catalysts for the innovative drug sector, particularly mentioning ESMO, ASCO, and WCLC as critical events for Chinese pharmaceutical companies [20] Weekly New Drug Market Review - From October 20 to October 26, 2025, the top five gainers in the new drug sector were: - 欧康维视 (+8.87%) - 君圣泰 (+8.21%) - 诺思兰德 (+7.07%) - 友芝友 (+4.42%) - 海创药业 (+3.73%) - The top five losers were: - 康宁杰瑞 (-17.72%) - 北海康成 (-14.42%) - 创胜集团 (-14.29%) - 宜明昂科 (-13.40%) - 来凯医药 (-12.40%) [16][17] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas volume certainty after MNC certification: - PD-1 upgraded product: 三生制药 - GLP-1 asset: 联邦制药 - ADC assets: 科伦博泰, 百利天恒 2. Potential heavyweights for overseas MNC authorization: - PD-1 upgraded products: 康方生物, 信达生物 - Breakthroughs in autoimmune fields: 益方生物, 中国抗体 - Innovative target ADC: 复宏汉霖, 石药集团 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Beneficiaries of medical insurance directory: 恒瑞医药, 康诺亚, 迈威生物, 智翔金泰, 海创药业 - Beneficiaries of commercial insurance innovative drug directory: 药明巨诺, 科济药业 [2][20] New Drug Approval and Acceptance - This week, four new drug or new indication applications were approved, and five new drug or new indication applications were accepted in the domestic market [9] - A total of 46 new drug clinical applications were approved, and 31 new drug clinical applications were accepted [10] Key Domestic Market Events - 信达生物 announced a global strategic partnership with Takeda to accelerate the development of new generation tumor immunotherapy and antibody-drug conjugate therapies [11] - 康宁杰瑞 and 石药集团 announced that their HER2 bispecific antibody-drug conjugate JSKN003 received breakthrough therapy designation from the CDE [11] - 和黄医药 presented clinical data for HMPL-A251 at the AACR-NCI-EORTC conference [11] Key Overseas Market Events - 罗氏 received FDA approval for Gazyva/Gazyvaro for the treatment of active lupus nephritis in adult patients [12] - Electra Therapeutics announced that its therapy ELA026 received breakthrough therapy designation from the FDA and PRIME qualification from the EMA [12] - 安斯泰来 announced that the FDA accepted its supplemental biologics license application for the antibody-drug conjugate Padcev in combination with Keytruda [12]

华盛锂电10月26日公告，2025年第三季度实现营业收入1.89亿元，同比增长46.89%；归属于上市公司股 东的净利润亏损3023.56万元；基本每股收益-0.19元。 ...

Core Insights - The company reported a revenue increase of 46.89% year-on-year, reaching RMB 189 million in the third quarter of 2025 [1] - The net loss for the quarter was RMB 30.24 million, with a basic loss per share of RMB 0.19 [1] - The revenue growth was primarily driven by increased market demand and a significant rise in product sales volume [1] Financial Performance - Revenue for Q3 2025: RMB 189 million, up 46.89% year-on-year [1] - Net loss for Q3 2025: RMB 30.24 million [1] - Basic loss per share: RMB 0.19 [1] Market Dynamics - The increase in revenue is attributed to heightened market demand [1] - A substantial increase in product sales volume contributed to the revenue growth [1]

公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人沈鸣、主管会计工作负责人任国平及会计机构负责人（会计主管人员）杨敏保证季度 报告中财务信息的真实、准确、完整。 江苏华盛锂电材料股份有限公司 2025 年第三季度报告 证券代码：688353 证券简称：华盛锂电 江苏华盛锂电材料股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 末比上年同期 | | | | 动幅度(%) | | 增减变动幅度 | | | | | | (%) | | 营业收入 | 188,702,527.53 | 46.8 ...

格隆汇10月26日丨华盛锂电(688353.SH)公布2025 年第三季度报告，2025年7-9月，公司营业收入为人民 币1.89亿元，同比增长46.89%，净亏损为人民币3023.56万元，基本每股亏损为人民币0.19元。 公告显示，营收增长主要由于市场需求增加，产品销售数量大幅增加所致。 ...

智通财经APP讯，华盛锂电(688353.SH)发布2025年三季度报告，该公司前三季度营业收入为5.39亿元， 同比增长62.29%。归属于上市公司股东的净亏损为1.03亿元。归属于上市公司股东的扣除非经常性损益 的净亏损为1.16亿元。基本每股亏损为0.66元。 ...

Core Viewpoint - The company, Huasheng Lithium Battery, clarified that its main product is lithium battery electrolyte additives and does not involve the production and sales of potassium hexafluorophosphate [1] Company Summary - Huasheng Lithium Battery's primary focus is on lithium battery electrolyte additives [1] - The company does not engage in the production or sales of potassium hexafluorophosphate, which is a different segment within the lithium battery supply chain [1]

Group 1 - The stock price of Huasheng Lithium Electric (688353.SH) fell by 4.75% to 43.31 yuan as of the market close [1] - Huasheng Lithium Electric was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 13, 2022, with an issuance of 28 million shares at a price of 98.35 yuan per share [1] - The highest price recorded for the stock was 129.20 yuan on July 15, 2022, marking a significant decline as it is currently in a state of breaking [1] Group 2 - The total funds raised from the initial public offering (IPO) amounted to 2.754 billion yuan, with a net amount of 2.567 billion yuan after deducting issuance costs of 187 million yuan [1] - The net funds raised exceeded the original plan by 1.867 billion yuan, with the company initially aiming to raise 700 million yuan for various projects [1] - The issuance costs for the IPO were 186.8 million yuan, which included underwriting and sponsorship fees totaling 143.1 million yuan [1] Group 3 - On May 10, 2023, Huasheng Lithium Electric announced a profit distribution plan, which included a cash dividend of 1 yuan per share and a capital reserve increase of 0.45 shares per share for all shareholders [2] - The record date for the equity distribution was set for May 9, 2023, with the ex-dividend date on May 10, 2023 [2]